Starton Therapeutics
Bio:
Starton Therapeutics is a Phase 2 clinical-stage biotechnology company transforming standard-of-care therapies through Temporal Controlled Pharmacology. By engineering controlled, low-dose delivery of approved medicines, Starton addresses the limits of conventional intermittent dosing, such as toxic peak spikes ( ) and subtherapeutic troughs, enabling patients to stay on treatment longer, potentially improving survival. Startons lead candidate, STAR-LLD, is a controlled low-dose formulation of lenalidomide advancing in multiple myeloma and lymphoma in combination with T-cell
engager and CAR-T therapies.